Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), The Procter & Gamble Company (PG): Beware of These “Safe” Dow Stocks

Lately, many investors have sought protection from a potential downturn by turning to low-volatility stocks, which they perceive as somehow being safer than higher-volatility stocks. Yet even among the 30 blue-chip stocks in the Dow Jones Industrials , you’ll find that low volatility is no guarantee of protection during downdrafts in the overall market.

Pfizer Inc. (NYSE:PFE)

Why low volatility seems appealing

Over the past year or so, low-volatility stocks have gained notoriety as being better long-term performers than their higher-volatility counterparts. Several studies have established that when you look at long-term returns, low-volatility stocks often produce better results than high-volatility stocks, even though the greater risk involved with high-volatility stocks should theoretically reward investors with higher returns.

But often, phenomena such as low-volatility stock outperformance prove vulnerable once investors grab onto strategies that seek to exploit historical share-price behavior. Recently, we’ve seen exactly that vulnerability within the Dow.

A short-term reversal of fortune for low-vol stocks

From May 28 to June 5, the Dow dropped almost 450 points, or about 3%. Based on past history, what investors would have expected was for low-volatility stocks to post more modest declines while high-volatility stocks dropped more sharply.

Yet the actual returns of many of the Dow’s components point to the contrary. Pfizer Inc. (NYSE:PFE) and The Procter & Gamble Company (NYSE:PG) both lost more than 5% despite having betas that would suggest only half the volatility of the overall market. Verizon Communications Inc. (NYSE:VZ) also weighed in with an almost 5% pullback even with a beta of 0.8.

Has the low-vol strategy stopped working?

The key to understanding these results rests on a few observations. First and foremost, judging a long-term strategy over a period of a single week is completely unreasonable. Even a fully functional strategy can produce aberrant results in the short run.

But the other thing to note is that as these low-volatility stocks have gotten popular, their prices have risen. In particular, The Procter & Gamble Company (NYSE:PG) has the distinction of being in the defensive consumer-staples industry, which has been a place where many investors have turned looking for safety. Similarly, Pfizer Inc. (NYSE:PFE) and Verizon Communications Inc. (NYSE:VZ) are both high-dividend stocks, which have been in high demand given the low interest rate environment. An upturn in bond yields has weighed on many dividend stocks, even those with relatively low volatilities.

Don’t jump to conclusions

The key takeaway from the current behavior of low-volatility Dow stocks is that even a completely valid strategy can produce undesirable results when it gets too popular. Long-term investors should actually hope that more short-term-focused investors lose faith in the low-vol strategy, as that would make the strategy more likely to work in the future.

The article Beware of These “Safe” Dow Stocks originally appeared on and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool recommends Procter & Gamble.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!